Condition: FGF23-related Hypophosphataemic Rickets and Osteomalacia · Sponsor: Kyowa Kirin Korea Co., Ltd.
The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of CRYSVITA injection 10, 20, and 30mg, equivalent to in routine clinical settings
This description comes directly from the study's public registry record.
HaeMi Park · +82-10-3378-3471 · haemi.park.m8@kyowakirin.com
Always discuss trial participation with your own doctor first.
| Wonju Severance Christian Hospital | Wŏnju, Gangwon-do, South Korea | Recruiting |
| Ajou University Hospital | Suwon, Gyeonggi-do, South Korea | Recruiting |
| Yangsan Pusan National University Hospital | Yangsan, Gyeongsangnam-do, South Korea | Recruiting |
| Chonnam National University Hospital | Gwangju, Jeollanam-do, South Korea | Recruiting |
| Chungnam National University Sejong Hospital | Sejong, Sejong Special Self-Governing City, South Korea | Recruiting |
| Inje University Busan Paik Hospital | Busan, South Korea | Recruiting |
| Pusan National University Hospital | Busan, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
| Severance Hospital | Seoul, South Korea | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06202027